Key Takeaways
- Sharp QoQ revenue recovery, but still below prior year: Revenue jumped 62.6% QoQ to ₹23.29 crores as core pharma intermediates rebounded, yet remained 23% lower YoY because European demand stayed subdued and customers deferred orders.
- Margin compression from input costs and operating leverage: EBITDA margin fell to 16.99% from 23.3% QoQ and 31.7% YoY as raw material prices rose significantly and fixed costs spread over still-recovering volumes, though absolute EBITDA still rose 17% QoQ.
- The pipeline is shifting decisively toward CRAMS and specialty chemicals: Two new pharma intermediates launched commercially, a Southeast Asia CRAMS project is targeting Q1 FY28 commercial supply, and management expects future revenue majority from CRAMS in agrochemicals, electronics and semiconductors, with pharma going softer.
- Balance sheet strengthened despite the soft patch: Total borrowings reduced to ₹25.99 crores, cash and investments exceeded borrowings, trade receivables fell sharply, and finance costs halved YoY for H1, giving the company room to fund expansion from internal accruals.
- What to watch next quarter: Whether the CRAMS project receives commercial supply clarity by March-end as guided, whether European demand and inventory normalization actually materialize, and whether the two new pharma intermediates gain export traction.
Revenue Recovery & Headwinds
- QoQ rebound driven by core business: Revenue rose 62.6% QoQ to ₹23.29 crores, led by the core pharmaceutical intermediates business, with sharpened domestic focus partly offsetting softer exports and improved traction from European customers.
- YoY decline still significant: Revenue was 23% lower than Q2 FY26 (₹30.32 crores) because European demand remained subdued, customers deferred orders amid geopolitical uncertainty, and raw material markets were volatile.
- Domestic shift was partly strategic, not purely defensive: Domestic sales rose to roughly half of exports in Q2; some projects leveraged existing chemistry for products India imports from China where decent margins can be made, not merely a stopgap for weak European demand.
- Old European distribution agreement ended: The traditional European partner who handled old business was terminated, which contributed to the downfall in figures and reflects a deliberate channel reset.
- Lumpiness tied to customer concentration: Recent lumpiness was primarily due to heavy reliance on European customers; management had already anticipated the need to broaden the customer base.
- Finished-goods inventory piled up: European customers deferred procurement and reduced stock-keeping due to raw material and finished-product price volatility; management expects normalization as geopolitical conditions and volatility calm down over the next few quarters.
Gunjan Kothia: "Some of the projects we realized that we can use our existing chemistry to leverage the products that India does import from China and where we can still make a decent margin. So this was a quite strategic move."
Margin Dynamics
- Margin compressed on two fronts: EBITDA margin fell to 16.99% in Q2 FY27 from 23.3% in Q1 and 31.7% in Q2 FY26 because volumes, though improved QoQ, remained below earlier levels, pressuring margins given meaningful fixed costs, while raw material prices rose significantly and remained volatile, causing operating expenses to rise 76% QoQ versus revenue growth of 62%.
- Absolute EBITDA still improved: EBITDA rose 17% QoQ to ₹3.94 crores even as margin contracted, because revenue growth outpaced the fixed-cost absorption gap.
- Input cost normalization expected: Management expects input costs to ease as geopolitical conditions stabilize, and margins to normalize as sales return to earlier levels.
Pipeline & New Product Traction
- Two new pharma intermediates launched commercially: One for anti-diabetic application, one for cardiovascular application; both received encouraging domestic response, with plans to take them to export markets in coming quarters.
- CRAMS specialty chemicals project advancing: The Southeast Asia project has completed pilot trials, batches are undergoing stability testing, and commercial supplies are expected from Q1 FY28. A second specialty product in the same region has cleared laboratory trials and moved to pilot stage.
- European molecules progressing: Positive progress on two molecules in Europe, one for pharmaceutical applications and one for agrochemical applications.
- CRAMS project delays tied to stringent specifications: The product goes into an industry requiring very stringent specifications; approvals from the customer's end have taken longer than expected because the entire value chain, including the customer's end-product testing with their own customer, must complete testing.
- Switching cost advantage embedded: The multi-party approval chain for stringent-spec products increases switching costs significantly; if the customer finds an alternate vendor, they would need to go through the whole chain again, making switching much more difficult.
- Pipeline depth: Currently working on 10+ projects across R&D, pilot, and commercial scale-up at any point in time.
Gunjan Kothia: "If the customer, our customer, finds an alternate vendor, they will need to go through this whole chain, and so the switching will be much more difficult."
Strategic Direction & Portfolio Reshaping
- Future revenue majority expected from CRAMS: Management stated most future revenue would come from CRAMS, whether agrochemical, electronics, or semiconductor, with pharmaceutical going softer; domestic participation to continue where decent margins are achievable, including upcoming electronics and semiconductor industry in India.
- Product selection philosophy: The company will be inclined more toward SpecChem and CRAMS projects; products will be selected purely based on chemistry expertise developed, whether pharma, electronics, or agrochemicals.
- Regulatory strategy defined: Planning to get up to WHO GMP, which is in the pipeline; will not pursue US FDA or Korean FDA because the company will not be participating in very advanced N-1 intermediates; focus is on hard-to-make chemistry-driven projects.
- Southeast Asia expansion: The company has expanded to the whole Southeast Asia market, especially the electronics industry, to leverage chemistry expertise and gain higher-value, higher-margin products.
- Confidence stems from customer quality: Management's confidence stems from working with top-tier customers worldwide; being a small player yet able to grab their attention and opportunities indicates both SGRL and the customers are confident in delivery capability.
Gunjan Kothia: "In the future, most of our revenue would be from the CRAMs, either it be agrochemical or electronics or semiconductor. On the pharmaceutical, we are going a bit on a softer side, so majority of our revenue would be from agro and semiconductor. Followed by pharmaceutical as we move ahead."
Gunjan Kothia: "These innovative companies or these top-tier companies, they don't entertain unless and until they think the manufacturer is capable to deliver this product."
Capacity & Infrastructure Build-Out
- Plant 7A completed: Construction finished; water trials completed; will soon start using for commercial production.
- Pilot plant commissioned: A new pilot plant was commissioned recently, which has been a critical aspect of trial and error and process development, helping internal understanding of projects.
- Expansion is demand-signal driven: Management stated they only put up fresh capacity when they get meaningful signal from customers, not in anticipation; will build capacity stage by stage as and when meaningful signals, forecasts, or contracts are received.
- Ample land available for rapid expansion: Enough land parcel for 3–4 more blocks at Ankleshwar; a large land parcel is available within the hedge for significant and rapid expansion, with sufficient and appropriate licenses already in place; Dahed site only if required.
- Capital raising option kept open: If expansion is needed on multiple sites, that option will be explored; as of now, current expansion is done from internal accruals and capital at hand has been sufficient.
- R&D strengthening underway: Building in-house strength by recruiting more chemists and taking external help from universities worldwide to develop niche capabilities; university names not disclosed.
Gunjan Kothia: "Wee are slowly putting up the blocks to cater to this new projects as and when required. ... we keep on expanding and putting up the infrastructure. And also, to talk about the available land parcel and land space, we have ample land space in Ankleshwar side. And so the construction will continue on the Ankleshwar site, and only if required, then it will be shifted to the Dahed site."
Balance Sheet & Working Capital
- Borowings reduced: Total borrowings reduced to ₹25.99 crores from ₹30.67 crores at March-end, mainly via short-term borrowing reduction.
- Net cash positive: Cash and investments at ₹28.74 crores exceeded total borrowings.
- Trade receivables improved: Reduced to ₹21.12 crores from ₹32.57 crores at March-end.
- Finance cost halved: Finance cost halved YoY for H1.
- Inventory normalization expected: Finished-goods inventory piled up in H1 FY27 due to European customer deferrals; management expects normalization over the next few quarters as geopolitical situation and volatility calm down.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Core business recovery | Core pharmaceutical intermediates business to recover to earlier levels, based on improved European customer traction and domestic focus | Next few quarters |
| Margin normalization | Margins to normalize as sales return to earlier levels and input costs ease with geopolitical stabilization | Next few quarters |
| New products export expansion | Take the2 new pharmaceutical intermediates (anti-diabetic, cardiovascular) to export markets | Coming quarters |
| Southeast Asia CRAMS commercial supply | Commercial supplies to begin for the first specialty chemical project | Q1 FY28 |
| CRAMS commercial supply clarity | Clarity on commercial supply for the CRAMS project expected; commercialization eventually starting in Q1 of next year | By end of March (Q4 FY27) |
| CRAMS peak utilization | CRAMS projects expected to reach peak commercial quantities; at peak, plant utilization around80% in total at SGR | In3 years |
| Revenue doubling visibility | Same visibility that revenue can double with existing products | Next3–4 years |
| Inventory normalization | Inventory and stock to return to normal levels as geopolitical situation and volatility calm down | Next few quarters |
| Regulatory approval | Planning to get up to WHO GMP | In pipeline (undated) |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue from operations | ₹23.29 cr, +62.62% QoQ and -23% YoY |
| EBITDA (excl. other income and exceptional items) | ₹3.94 cr, +17% QoQ and -59% YoY |
| EBITDA margin | 16.99%, vs 23.3% in Q1 FY27 and 31.7% in Q2 FY26 |
| Profit after tax | ₹1.63 cr, +46% QoQ and -67% YoY |
| Earnings per share | ₹1.28 |
| Operating expenses | ₹19.36 cr, +76% QoQ vs revenue growth of 62% QoQ |
| Total borrowings | ₹25.99 cr, down from ₹30.67 cr at end of March FY26 |
| Cash and bank balances plus investments | ₹28.74 cr, higher than total borrowings |
| H1 FY27 cash from operating activities | ₹14.64 cr, vs ₹17.66 cr in H1 FY26 |
| Trade receivables | ₹21.12 cr, down from ₹32.57 cr at end of March FY26 |
| Capital work in progress | ₹16.6 cr, up from ₹12.38 cr at end of March FY26 |
| H1 FY27 finance cost | ₹0.89 cr, down from ₹1.95 cr in H1 FY26 |
| CRAMS projects in pipeline | 10+ projects across R&D, pilot, and commercial scale-up stages |
| Anticipated asset turnover on new investments | ~2 times |
| Anticipated payback period on new projects | 3 to 4 years from commercialization start |
| Internal ROCE benchmark | 20 to 25% (per an analyst's math, confirmed by management) |